CR20220275A - Antagonistas heterocíclicos de nmda - Google Patents

Antagonistas heterocíclicos de nmda

Info

Publication number
CR20220275A
CR20220275A CR20220275A CR20220275A CR20220275A CR 20220275 A CR20220275 A CR 20220275A CR 20220275 A CR20220275 A CR 20220275A CR 20220275 A CR20220275 A CR 20220275A CR 20220275 A CR20220275 A CR 20220275A
Authority
CR
Costa Rica
Prior art keywords
nmda antagonists
heterocyclic
heterocyclic nmda
migraine
dementia
Prior art date
Application number
CR20220275A
Other languages
English (en)
Inventor
Makoto Kamata
Satoshi Yamamoto
Minoru Nakamura
Fumie Yamaguchi
Takeshi Wakabayashi
Kouichi Iwanaga
Shuhei Ikeda
Atsuko Ochida
Norio Oyabu
Masataka Murakami
Yuya Oguro
Jumpei Aida
Takafumi Yukawa
Taisuke Tawaraishi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CR20220275A publication Critical patent/CR20220275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Un compuesto de la fórmula (I): <!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"> <v:stroke joinstyle="miter"/> <v:formulas> <v:f eqn="if lineDrawn pixelLineWidth 0"/> <v:f eqn="sum @0 1 0"/> <v:f eqn="sum 0 0 @1"/> <v:f eqn="prod @2 1 2"/> <v:f eqn="prod @3 21600 pixelWidth"/> <v:f eqn="prod @3 21600 pixelHeight"/> <v:f eqn="sum @0 0 1"/> <v:f eqn="prod @6 1 2"/> <v:f eqn="prod @7 21600 pixelWidth"/> <v:f eqn="sum @8 21600 0"/> <v:f eqn="prod @7 21600 pixelHeight"/> <v:f eqn="sum @10 21600 0"/> </v:formulas> <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/> <o:lock v:ext="edit" aspectratio="t"/></v:shapetype><v:shape id="¿_x0020_4" o:spid="_x0000_i1025" type="#_x0000_t75" alt="" style='width:178pt;height:95.5pt'> <v:imagedata o:href="cid:image019.png@01D87F1F.B444A160"/></v:shape><![endif]--> (I), o una sal del mismo que puede tener una acción antagonista contra un receptor NMDA que incluye una subunidad NR2B y puede ser útil como agente profiláctico o terapéutico para la depresión, trastorno bipolar, migraña, dolor, un síntoma periférico de la demencia o similares.
CR20220275A 2019-11-14 2020-11-12 Antagonistas heterocíclicos de nmda CR20220275A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019206311A JP2021080177A (ja) 2019-11-14 2019-11-14 複素環化合物及びその用途
PCT/IB2020/000962 WO2021094832A1 (en) 2019-11-14 2020-11-12 Heterocyclic nmda antagonists

Publications (1)

Publication Number Publication Date
CR20220275A true CR20220275A (es) 2023-02-17

Family

ID=74141594

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220275A CR20220275A (es) 2019-11-14 2020-11-12 Antagonistas heterocíclicos de nmda

Country Status (20)

Country Link
US (3) US20230002318A1 (es)
EP (1) EP4058430A1 (es)
JP (2) JP2021080177A (es)
KR (1) KR20220102629A (es)
CN (1) CN114728900A (es)
AR (1) AR120452A1 (es)
AU (1) AU2020385250A1 (es)
BR (1) BR112022008367A2 (es)
CA (1) CA3158352A1 (es)
CL (1) CL2022001241A1 (es)
CO (1) CO2022008012A2 (es)
CR (1) CR20220275A (es)
DO (1) DOP2022000099A (es)
EC (1) ECSP22037602A (es)
IL (1) IL292639A (es)
JO (1) JOP20220108A1 (es)
MX (1) MX2022005778A (es)
PE (1) PE20221767A1 (es)
TW (1) TW202132268A (es)
WO (1) WO2021094832A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245003T3 (es) 1996-08-27 2005-12-16 Praecis Pharmaceuticals Incorporated Moduladores de la agregacion de peptidos beta-amiloides que comprenden d-aminoacidos.
CA2344412A1 (en) * 1998-09-21 2000-03-30 Takeda Chemical Industries, Ltd. Thiol compound, their production and use
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
JP2003512422A (ja) * 1999-10-29 2003-04-02 メルク シャープ エンド ドーム リミテッド ベンズイミダゾールｎｍｄａ／ｎｒ２ｂアンタゴニストを使用する疼痛の治療方法
EP1500658A4 (en) * 2002-04-26 2007-04-11 Takeda Pharmaceutical NEW THIOL DERIVATIVE, METHOD FOR ITS PRODUCTION AND ITS USE
AR057218A1 (es) * 2005-12-15 2007-11-21 Astra Ab Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
WO2009004430A1 (en) * 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
DK3110434T3 (en) 2014-02-24 2019-01-14 Takeda Gmbh UTI FUSION PROTEINS
WO2018205935A1 (zh) 2017-05-09 2018-11-15 浙江大学 治疗抑郁症的方法和药物组合物
JP6806735B2 (ja) 2018-05-30 2021-01-06 矢崎総業株式会社 車両用回路体および車両用回路体の製造方法
SG11202103325WA (en) 2018-10-18 2021-05-28 Essa Pharma Inc Androgen receptor modulators and methods for their use
CN114502539A (zh) 2019-03-28 2022-05-13 埃萨制药股份有限公司 包含雄激素受体的抑制剂的药物组合物和组合及其用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Also Published As

Publication number Publication date
PE20221767A1 (es) 2022-11-11
CN114728900A (zh) 2022-07-08
US20230134307A1 (en) 2023-05-04
JP2023502030A (ja) 2023-01-20
US11827601B2 (en) 2023-11-28
EP4058430A1 (en) 2022-09-21
KR20220102629A (ko) 2022-07-20
AU2020385250A1 (en) 2022-06-30
JOP20220108A1 (ar) 2023-01-30
CO2022008012A2 (es) 2022-06-10
ECSP22037602A (es) 2022-06-30
BR112022008367A2 (pt) 2022-10-18
WO2021094832A8 (en) 2022-06-02
US20230150934A1 (en) 2023-05-18
DOP2022000099A (es) 2022-08-31
WO2021094832A1 (en) 2021-05-20
TW202132268A (zh) 2021-09-01
CA3158352A1 (en) 2021-05-20
AR120452A1 (es) 2022-02-16
CL2022001241A1 (es) 2023-02-03
US11834409B2 (en) 2023-12-05
US20230002318A1 (en) 2023-01-05
JP2021080177A (ja) 2021-05-27
IL292639A (en) 2022-07-01
MX2022005778A (es) 2022-06-09

Similar Documents

Publication Publication Date Title
PH12017501140A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
PH12018501413A1 (en) Substituted thiohydantoin derivatives as androgen receptor antagonists
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
NZ725399A (en) Macrocylic pyrimidine derivatives
MX2022005778A (es) Antagonistas heterociclicos de nmda.
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
NZ739139A (en) Dopamine d3 receptor antagonists having a bicyclo moiety
PH12021550048A1 (en) Selective estrogen receptor degraders.
MX2021001786A (es) Antagonistas de integrina.
NZ738990A (en) Cgrp receptor antagonists
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
ZA202305624B (en) Amorphous form of a complement component c5a receptor
AU2019241765A8 (en) Heterocyclic compound and use thereof
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
MX2020013352A (es) Tratamiento para migrañas.
MX2017010630A (es) Derivado de imidazopirimidina e imidazotriazina, y composicion farmaceutica que lo comprende.
TN2017000248A1 (en) Cgrp antagonist peptides
JOP20180070B1 (ar) مثبطات إنزيم كيناز بروتين يتفاعل مع مستقبل 1
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.